Track Zymeworks Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Zymeworks Inc. ZYME · Stock Open Zymeworks Inc. in new tab

26.24 USD
P/E
49.51
EPS
0.53
P/B
7.23
ROE
14.98
Beta
1.30
Target Price
43.29 USD
Zymeworks Inc. logo

Zymeworks Inc.

🧾 Earnings Recap – Q1 2026

Zymeworks shares were unchanged following the quarter, reflecting investor indifference to a steep revenue decline offset by modest improvements in expenses and advancing pipeline updates, while the widening net loss and reduced milestone income raised concerns.

  • Revenue fell sharply to $2.4 million from $27.1 million year-over-year, primarily due to the absence of nonrecurring clinical milestone payments received in Q1 2025.
  • Operating expenses decreased modestly to $49.5 million from $52.7 million, driven by lower R&D spend on late-stage and discontinued programs but partly offset by increased early-stage investment and leadership transition costs.
  • Net loss widened to $44.2 million from $22.6 million in the prior year quarter, reflecting the revenue drop and ongoing investment in development activities.
  • Advances in the pipeline include progressing regulatory and commercial milestones for zanidatamab and initial positive early-stage clinical data for ADC candidates presented at AACR.
  • Management emphasized a strategic focus on integrating R&D with royalty aggregation but did not provide updated financial guidance or concrete near-term revenue visibility beyond milestone expectations.
📅
Loading chart...
Key Metrics
Earnings dateMarch 1, 2027
P/E49.51
EPS0.53
Book Value3.63
Price to Book7.23
Debt/Equity20.57
% Insiders1.517%
Growth
Revenue Growth8.29%
Estimates
Forward P/E50.50
Forward EPS0.52
Target Mean Price43.29

DCF valuation

Model fair value for Zymeworks Inc. (ZYME)
Result
Sign in to run the valuation for ZYME.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
14 analysts · consensus Strong buy · mean target 43.29 USD (low 35.00, high 60.00) · as of 15 Nov 2026
Low 35.00
Mean 43.29
High 60.00
Price 26.24
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Zymeworks Inc. Logo Zymeworks Inc. Analysis (ZYME)

Canada Health Care Official Website Stock

Is Zymeworks Inc. a good investment? Zymeworks Inc. (ZYME) is currently trading at 26.24 USD. Market analysts have a consensus price target of 43.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 49.51. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Zymeworks Inc. is expected to release its next earnings report on March 1, 2027. The market consensus estimate for Forward EPS is 0.52.

Investor FAQ

Does Zymeworks Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Zymeworks Inc.?

Zymeworks Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 1, 2027. The company currently has a trailing EPS of 0.53.

Company Profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Exchange Ticker
NYQ (United States) ZYME
BER (Germany) 0OX.BE
DUS (Germany) 0OX.DU
FRA (Germany) 0OX.F
MUN (Germany) 0OX.MU
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion